Amelioration of Head and Neck Radiation-Induced Mucositis and Distant Marrow Suppression in Fanca-/- and Fancg-/- Mice by Intraoral Administration of GS-Nitroxide (JP4-039)

Radiat Res. 2018 Jun;189(6):560-578. doi: 10.1667/RR14878.1. Epub 2018 Mar 27.

Abstract

Squamous cell carcinomas of the head and neck are appearing with increased frequency in both marrow transplanted and non-transplanted Fanconi anemia (FA) patients. FA patients commonly display radiosensitivity of epithelial tissues, complicating effective radiotherapy. Fancd2-/- mice (C57BL/6J and 129/Sv background) demonstrate epithelial tissue sensitivity to single-fraction or fractionated irradiation to the head and neck and distant marrow suppression (abscopal effect), both ameliorated by intraoral administration of the mitochondrial-targeted antioxidant, GS-nitroxide, JP4-039. We now report that mice of two other FA genotypes, Fancg-/- (B6) and the most prevalent human genotype Fanca-/- (129/Sv), also demonstrate: 1. reduced longevity of hematopoiesis in long-term bone marrow cultures; 2. radiosensitivity of bone marrow stromal cell lines; and 3. head and neck radiation-induced severe mucositis and abscopal suppression of distant marrow hematopoiesis. Intraoral administration of JP4-039/F15, but not non-mitochondrial-targeted 4-amino-Tempo/F15 or F15 alone, prior to each radiation treatment ameliorated both local and abscopal radiation effects. Head and neck irradiated TGF-β-resistant SMAD3-/- (129/Sv) mice and double-knockout SMAD3-/- Fancd2-/- (129/Sv) mice treated daily with TGF-β receptor antagonist, LY364947, still displayed abscopal bone marrow suppression, implicating a non-TGF-β mechanism. Thus, amelioration of both local normal tissue radiosensitivity and distant marrow suppression by intraoral administration of JP4-039 in Fancg-/- and Fanca-/- mice supports a clinical trial of this locally administered normal tissue radioprotector and mitigator during head and neck irradiation in FA patients.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Animals
  • Bone Marrow / drug effects*
  • Bone Marrow / pathology
  • Bone Marrow / radiation effects
  • Cell Survival / drug effects
  • Cell Survival / radiation effects
  • Fanconi Anemia Complementation Group A Protein / deficiency
  • Fanconi Anemia Complementation Group G Protein / deficiency
  • Head and Neck Neoplasms / radiotherapy*
  • Hematopoiesis / drug effects
  • Hematopoiesis / radiation effects
  • Interleukin-3 / metabolism
  • Mice
  • Mitomycin / pharmacology
  • Mucositis / drug therapy*
  • Mucositis / metabolism
  • Mucositis / pathology
  • Nitrogen Oxides / administration & dosage*
  • Nitrogen Oxides / pharmacology*
  • Nitrogen Oxides / therapeutic use
  • Radiation Injuries, Experimental / drug therapy*
  • Radiation Injuries, Experimental / metabolism
  • Radiation Injuries, Experimental / pathology
  • Radiation Tolerance / drug effects
  • Radiation Tolerance / radiation effects
  • Radiation-Protective Agents / administration & dosage
  • Radiation-Protective Agents / pharmacology*
  • Radiation-Protective Agents / therapeutic use
  • Signal Transduction / drug effects
  • Signal Transduction / radiation effects
  • Transforming Growth Factor beta / metabolism

Substances

  • Fanconi Anemia Complementation Group A Protein
  • Fanconi Anemia Complementation Group G Protein
  • Interleukin-3
  • JP4-039
  • Nitrogen Oxides
  • Radiation-Protective Agents
  • Transforming Growth Factor beta
  • Mitomycin